中慧生物－Ｂ 02627Prospectus Information

Prospectus Information
返回 Stock Info Prospectus Allotment Results Allotment Profile Expected Lots
IPO Timeline
Broker Deadline
2025-08-05
Morning deadline
HKEX Deadline
2025-08-05
Noon deadline
Broker Results (T-2)
2025-08-07
Some brokers release in afternoon
Grey Market (T-1)
2025-08-08
Afternoon
HKEX Allotment (T-1)
2025-08-08
Evening
Registrar Allotment (T-1)
2025-08-08
Evening
Listing Day (T)
2025-08-11
First day of trading
Company Overview
Stock Name中慧生物－Ｂ
Stock Code02627
Company Full Name中慧生物－Ｂ
IndustryBiotech & Pharma
Principal Activitiesindustry veteran with over 15 years of experience in the biotechnology and pharmaceutical industries
Listing Date2025-08-11
Listing Rules EraNew Rules (after Aug 2025)
Listing Rules ChapterChapter 18A
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國 江蘇省泰州市 醫藥高新區 杏林路32號
Business Address (Hong Kong)248 Queen’s Road East Wanchai Hong Kong
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.abbbio.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo
Offering Information
Offering Mechanism Mechanism B
Offer PriceHK$ 12.90 / shares
Offer Price RangeFinal offer price only, no range
Lot Size200 shares
Entry ThresholdHK$ 2,580
Par ValueRMB 1.0 / shares
Offer Period2025-07-31 to 2025-08-05
Global Offering Shares33,442,600 shares
HK Public Offer Shares (Initial)3,344,260 shares (10.0%)
Public Offer Lots (Initial)16,721lots (8,360lots, 8,361lots)
International Placing Shares (Initial)30,098,340 shares (90.0%)
Offer Ratio~8.5%
Total Shares Post-IPO393,442,600 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share21.3%
Clawback Tiers机制B-无回补
Reallocation OptionNo
Total Global Offering SizeHK$ 431,409,540
Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 200 HK$ 2,580
2 lots 400 HK$ 5,160
3 lots 600 HK$ 7,740
4 lots 800 HK$ 10,320
5 lots 1,000 HK$ 12,900
6 lots 1,200 HK$ 15,480
7 lots 1,400 HK$ 18,060
8 lots 1,600 HK$ 20,640
9 lots 1,800 HK$ 23,220
10 lots 2,000 HK$ 25,800
15 lots 3,000 HK$ 38,700
20 lots 4,000 HK$ 51,600
25 lots 5,000 HK$ 64,500
30 lots 6,000 HK$ 77,400
35 lots 7,000 HK$ 90,300
40 lots 8,000 HK$ 103,200
45 lots 9,000 HK$ 116,100
50 lots 10,000 HK$ 129,000
100 lots 20,000 HK$ 258,000
150 lots 30,000 HK$ 387,000
200 lots 40,000 HK$ 516,000
250 lots 50,000 HK$ 645,000
300 lots 60,000 HK$ 774,000
350 lots 70,000 HK$ 903,000
400 lots 80,000 HK$ 1,032,000
450 lots 90,000 HK$ 1,161,000
500 lots 100,000 HK$ 1,290,000
1,000 lots 200,000 HK$ 2,580,000
1,500 lots 300,000 HK$ 3,870,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
2,000 lots 400,000 HK$ 5,160,000
2,500 lots 500,000 HK$ 6,450,000
3,000 lots 600,000 HK$ 7,740,000
3,500 lots 700,000 HK$ 9,030,000
4,000 lots 800,000 HK$ 10,320,000
4,500 lots 900,000 HK$ 11,610,000
5,000 lots 1,000,000 HK$ 12,900,000
6,000 lots 1,200,000 HK$ 15,480,000
7,000 lots 1,400,000 HK$ 18,060,000
8,361 lots 1,672,200 HK$ 21,571,380
Valuation & Financials
Market Cap (at Offer Price)HK$ 5,075,409,540
Pre-IPO Valuation (Last Round)To be extracted
P/E Ratio不适用（公司处于亏损状态）
Profit/Loss Status亏损人民币258.7百万元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted
First Day Performance
First Day CloseHK$ 33.28
First Day OpenHK$ 33.0
First Day Change157.98%
First Day Volume8992780.0
First Day Turnover297614000.0
Use of Proceeds
Use of Proceeds1、約63.6%或266.9百萬港元將分配至核心產品的開發及國內外注冊； 2、約18.1%或76.4百萬港元將用于其他在研疫苗的開發和注冊； 3、約8.4%或35.4百萬港元將分配至提升生產及商業化能力； 4、約4.9%或20.8百萬港元將分配至技術平臺的開發、升級及運營； 5、約5.0%或21.0百萬港元將分配至營運資金及其他一般公司用途。
Underwriting Syndicate
Joint Sponsors (2)
中信证券（香港）有限公司 CE AAK249 招银国际融资有限公司 CE AVM940
Overall Coordinators (2)
中信里昂证券有限公司 CE AAB893 招银国际融资有限公司 CE AVM940
Joint Global Coordinators (2)
中信里昂证券有限公司 CE AAB893 招银国际融资有限公司 CE AVM940
Joint Bookrunners (7)
中信里昂证券有限公司 CE AAB893 招银国际融资有限公司 CE AVM940 利弗莫尔证券有限公司 CE BJN764 富德证券有限公司 CE BHT984 雅利多证券有限公司 CE BDH167 中银国际亚洲有限公司 CE AET863 工银国际证券有限公司 CE ARO299
Joint Lead Managers (7)
中信里昂证券有限公司 CE AAB893 招银国际融资有限公司 CE AVM940 利弗莫尔证券有限公司 CE BJN764 富德证券有限公司 CE BHT984 雅利多证券有限公司 CE BDH167 中银国际亚洲有限公司 CE AET863 工银国际证券有限公司 CE ARO299
Capital Market Intermediaries (7)
中信里昂证券有限公司 CE AAB893 招银国际融资有限公司 CE AVM940 利弗莫尔证券有限公司 CE BJN764 富德证券有限公司 CE BHT984 雅利多证券有限公司 CE BDH167 中银国际亚洲有限公司 CE AET863 工银国际证券有限公司 CE ARO299
Service Providers
RoleInstitution
Legal Advisor to Company 年利达律师行
北京国枫律师事务所
北京市嘉源律师事务所
Legal Advisor to Sponsors/Underwriters 高伟绅律师行
通商律师事务所
Auditor and Reporting Accountant 德勤•关黄陈方会计师行
Industry Advisor 弗若斯特沙利文（北京）咨询有限公司上海分公司
Receiving Banks 中国银行（香港）有限公司
Cornerstone Investors
#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 嘉兴鑫扬及华泰资本投资（与华泰背对背总回报掉期及华泰客户总回报掉期有关） 13,000,000 USD 7,113,600 21.30% 1.80% 6 months 2026-02-11
Directors & Management
ChairmanMr. An Youcai
Company SecretaryMs. Zhang Yangyang
執行董事 (3)
#NameEnglish NameType
1 安有才 — 執行董事
2 李润香 — 執行董事
3 何一鸣 — 執行董事
非執行董事 (3)
#NameEnglish NameType
1 程千文 — 非執行董事
2 于建林 — 非執行董事
3 杜沐 — 非執行董事
獨立非執行董事 (6)
#NameEnglish NameType
1 李向明 — 獨立非執行董事
2 李晓青 — 獨立非執行董事
3 陈乘贝 — 獨立非執行董事
4 封浩 — 獨立非執行董事
5 王曙光 — 獨立非執行董事
6 王威 — 獨立非執行董事
Major Shareholders
Major Shareholders & HoldingsCONTROLLING SHAREHOLDERS (b) a Director with himself/herself or his/her close associates having material interests shall make full disclosure in respect of matters that may have conflict or potentially conflict with any of our interest at the meeting of our Board, shall abs
AI AI Analysis
!
The following content is generated by an AI model based on historical IPO data. It does NOT constitute investment advice, solicitation, or recommendation. Past subscription patterns and post-listing performance do not guarantee future results. Data may contain inaccuracies — always verify against official HKEX filings and prospectuses before making any investment decision.

Market Sentiment

With an offer price of HK$12.9 and an entry threshold of HK$2,580, the IPO drew an extraordinary oversubscription ratio of 4,007.64 times, signaling intense retail demand for this 18A biotech listing. The overall hit rate was a mere 9.87%, meaning only about one in ten applications succeeded, highlighting the fierce competition. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Tier Analysis

The tier distribution shows a stark inefficiency at the boundary: 甲尾 applicants, applying for 300,000 shares, could expect just 0.24 lots, while 乙头 subscribers with 400,000 shares saw an expected 0.6 lots—more than double the lots for only a 33% increase in shares. This indicates a disproportionately large jump in allocation probability when crossing into the B tier. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Demographics

Successful applicants were predominantly male (61.3%) with an average age of 42.8, and a striking 69.7% hailed from mainland China, underscoring the strong cross-border demand for Hong Kong biotech IPOs. Hong Kong residents accounted for just 29.5% of the allotment, pointing to a heavily mainland-driven investor base. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

AI-generated content. For informational purposes only. Not financial advice. Verify against official sources.
Offering Structure
Subscription Tiers
IPO Timeline
Disclaimer & Risk Warning

Site Nature: This website (cibo.qizai.ai) is an independent technology product showcase platform established by Panda Securities Limited (CE Number: BNC380). This website itself and all content displayed herein do not constitute and are not involved in any regulated activity or licensed service.

Not Investment Advice: The data on this page is automatically extracted from prospectus PDFs by AI and may contain omissions or errors. All information and data on this page are sourced from prospectuses and related historical documents, are not real-time data, and will not be automatically updated, reflecting historical information at the time of prospectus publication. All content is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, or guarantee. The output of this AI analysis tool should not be interpreted as investment opinion.

Decision Responsibility: Users should make investment decisions based on their own independent judgment and consult independent licensed financial advisors when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions made by users based on the information on this page.

Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated licensed services provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.

Panda Securities Limited is a licensed corporation regulated by the Hong Kong SFC (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). Use of this website constitutes acceptance of this disclaimer.

Cibo — IPO & Market Data Analytics